Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 17/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388122 | 0.83 | FBP1 (0.42) | FBP1CA2RAD51CA1CA9 | |
| SCHEMBL2914595 | 0.81 | FBP1 (0.44) | FBP1RAD51PTGES2 | |
| SCHEMBL1938334 | 0.80 | CA2 (0.44) | CA2CA1CA9PTGES2 | |
| SCHEMBL1137322 | 0.80 | PTGES2 (0.53) | CA2CA1CA9PTGES2 | |
| Hydrochloric Acid SCHEMBL27779742 | 0.79 | FBP1 (0.43) | FBP1RAD51 | |
| SCHEMBL5524092 | 0.77 | CA2 (0.44) | CA2CA1CA9 | |
| SCHEMBL2345395 | 0.77 | CA2 (0.41) | CA2CA1CA9PTGES2 | |
| SCHEMBL12203728 | 0.77 | DAO (0.42) | CA2PTGES2 | |
| SCHEMBL1510259 | 0.76 | FBP1 (0.48) | FBP1CA2RAD51CA1CA9 | |
| SCHEMBL7509729 | 0.75 | CA2 (0.41) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506000-B9 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-1506000-B1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| CN-101137643-A | Novel pyridine compounds | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1506000-A4 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6869964-B2 | Heterocyclicsulfonamide hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1506000-A1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040072761-A1 | Heterocyclicsulfonamide hepatitis C virus inhibitors | CAMPBELL JEFFREY ALLEN (US) | 2004-04-15 | — | — | US | disclosed |
| WO-2003099316-A1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072761-A1 | Heterocyclicsulfonamide hepatitis C virus inhibitors | HCCS, ANPEP, DNPEP | FBP1 1966/4885CA2 4339/4885RAD51 4733/4885 |
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | FBP1 734/4885CA2 2671/4885RAD51 3784/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | FBP1 243/4885CA2 3705/4885RAD51 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.